Novozymes Signs a Joint Development and Commercialization Agreement with Bactolife to Launch Feed Additive Ablacto+
- The companies collaborated to finish the development and commercialization of the biosolution Ablacto+ to reduce post-weaning diarrhea. The product is expected to be launched in 2026
- Additionally, the product uses binding proteins to stabilize the gut of piglets & reduce the need for antibiotic consumption thereby reducing the risk of antibiotic resistance development in both pigs and humans
- Novozymes will be responsible for developing and producing the final product and get the global exclusive marketing and sales responsibility. Additionally, ABLACTO+, a functional feed additive showed a promising result in large-scale swine trials
Ref: Globenewswire | Image: Novozymes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.